INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
Mycobacterium tuberculosis causes tuberculosis, a progressive granulomatous disease. A 6-month regimen of isoniazid, rifampicin, and pyrazinamide is the cornerstone of tuberculosis treatment. Compliance is crucial in tuberculosis treatment. Antituberculosis drugs can produce hepatotoxicity, a severe adverse reaction that can result in considerable morbidity and, in rare cases, death. This type of toxicity may alter how certain tuberculosis patients respond to treatment. Adverse effects frequently have a negative impact on compliance because they frequently need a change in treatment, which can have a poor impact on treatment result. In this study, we cover the metabolism and mechanisms of toxicity of isoniazid, rifampicin, and pyrazinamide, as well as risk factors and management of antituberculosis drug-induced hepatotoxicity. Hepatotoxicity is one of the furthermost serious adverse effects of anti-tuberculosis drugs (ATD). Although many risk factors have been associated with ATD-induced hepatotoxicity, their effect on hepatitis severity has not been studied systematically.
Keywords:
anti-tuberculosis; hepatotoxicity; drug induced liver injury (DILI).
Cite Article:
"Anti-tuberculosis Drug Induced Hepatotoxicity", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 10, page no.770 - 777, October-2022, Available :http://www.ijsdr.org/papers/IJSDR2210132.pdf
Downloads:
000337213
Publication Details:
Published Paper ID: IJSDR2210132
Registration ID:202338
Published In: Volume 7 Issue 10, October-2022
DOI (Digital Object Identifier):
Page No: 770 - 777
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn